Special Issue "Human Pluripotent Stem Cells for Therapy"


A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: closed (17 November 2014)

Special Issue Editor

Guest Editor
Dr. Bo Feng
School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
Website: http://www.sbs.cuhk.edu.hk/TeachingStaffDetails.asp?TE_NAME=FENG%20Bo
Interests: induced pluripotent stem cells; embryonic stem cells; neural stem cells; reprogramming; directed differentiation; regenerative medicine

Special Issue Information

Dear Colleagues,

Recent success in demonstrating the ability of naïve human pluripotent stem cells to survive and re-colonize robustly (after dissociating into single cells), represents a new milestone in stem cell research. In the meantime, the CRISPR/Cas9 nuclease, a newly emerged genomic editing tool that exhibits incomparable simplicity and efficiency when applied to multiple species and cell types, has pushed the boundaries of investigation and utility, with respect to human pluripotent stem cells. These advances are anticipated to have a great impact on both biomedical research and its industry. Also, more interesting discoveries can be expected in the near future.

In this Special Issue of Biomedicines, we invite front-line researchers to submit original research papers and review articles that explore the potential of these new advances to promote the therapeutic applications of human ES cells and iPS cells. Topics may include, but are not limited to:

  • Different methods used to establish naïve human pluripotent stem cells
  • Chemicals used for stem cell fate decision and reprogramming
  • Gene targeting in human pluripotent stem cells
  • New CRISPR/Cas9 nuclease applications

Dr. Bo Feng
Guest Editor


Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.


  • human embryonic stem cells
  • induced pluripotent stem cells
  • ground stage of mouse embryonic stem cells
  • naïve state of human embryonic stem cells
  • single cell dissociation of human embryonic stem cells
  • crispr/cas9
  • talen
  • engineered nuclease
  • engineered transcription factors
  • gene targeting

Published Papers

No papers have been published in this special issue yet.

Last update: 16 April 2014

Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert